Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MicroTech Medical (Hangzhou) Co., Ltd. Class H ( (HK:2235) ) has issued an update.
MicroTech Medical announced its audited consolidated annual results for 2024, highlighting a 36.5% increase in operating revenue to RMB345.62 million and a 51.5% rise in gross profit to RMB182.85 million. The company attributed this growth to the successful launch and commercialization of a new generation of Continuous Glucose Monitoring Systems (CGMS), which saw a revenue increase of 138.3%. Despite a net loss of RMB63.12 million, this marked a significant reduction from the previous year’s loss, driven by expanded sales, improved operational efficiency, and refined management. The company’s sufficient cash reserves, amounting to RMB1.697 billion, underscore its financial stability.
More about MicroTech Medical (Hangzhou) Co., Ltd. Class H
MicroTech Medical (Hangzhou) Co., Ltd. is a company based in China that focuses on providing medical products and services, particularly innovative solutions for diabetic patients. The company emphasizes product research and development, production, and commercialization to enhance the accessibility and coverage of its offerings.
YTD Price Performance: 0.98%
Average Trading Volume: 135,139
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.59B
Learn more about 2235 stock on TipRanks’ Stock Analysis page.